DNA Methylation and Disease Risk | Decoding Inflammation

By Decoding Inflammation · 2026-07-11 · 9 min

Your genome contains approximately three billion base pairs of DNA. The sequence of those base pairs — the order of the four nucleotide letters A, T, C, and G across the entire genome — is largely fixed from birth. The sequence changes only through mutation, which is rare and usually consequential. But how that sequence gets read, which genes the cell turns on, which it suppresses, and at what volume, changes continuously in response to the cell's environment. This layer of control is called epigenetics, the study of heritable changes in gene function that do not involve changes to the DNA sequence.

A review published in the International Journal of Molecular Sciences in February 2026 by Ladisa, Montenegro, Picerno, and colleagues from the University of Bari Aldo Moro described DNA methylation as the most extensively studied epigenetic mechanism and as a dynamic molecular interface linking environmental exposures, metabolic imbalance, inflammation, and disease development. The review confirmed that DNA methylation plays a central role in controlling gene expression across both physiological and pathological conditions.

WHAT DNA METHYLATION IS AND HOW IT WORKS

DNA methylation involves the addition of a methyl group, a carbon atom bonded to three hydrogen atoms, to a specific position on the DNA strand. This modification most commonly occurs at cytosine bases, one of the four DNA building blocks, when a cytosine sits immediately before a guanine in the sequence. This cytosine-guanine pairing at methylation sites carries its own name in the literature: a CpG dinucleotide.

When methyl groups accumulate at CpG sites in the promoter region of a gene, the region of DNA that controls how actively the gene gets transcribed, the cell reads that gene less frequently. The gene becomes silenced. The enzymes that add methyl groups to DNA are called DNA methyltransferases, abbreviated as DNMTs. The enzymes that remove them belong to a family called ten-eleven translocation proteins, abbreviated as TETs. The balance between DNMT and TET activity determines the methylation state of any given gene at any given moment.

THE ENVIRONMENTAL INPUT

The 2026 Bari review confirmed that DNA methylation responds dynamically to environmental exposures. Physical and chemical stressors alter the regulatory and enzymatic network that governs methylation patterns. Diet supplies the methyl groups that DNMTs require. Folate, vitamin B12, vitamin B6, choline, and methionine all participate in the one-carbon metabolism pathway, the cellular system that generates and distributes methyl groups. A diet deficient in these nutrients reduces the availability of methyl donors, which reduces the cell's capacity to methylate genes that require silencing to maintain normal function.

Toxic exposures, including air pollutants, heavy metals, and endocrine-disrupting chemicals, alter methylation patterns at specific gene loci. Research published in this field has documented aberrant methylation signatures in populations with elevated environmental chemical exposures. These signatures associate with increased incidence of inflammatory disease, cardiovascular disease, and cancer.

THE INFLAMMATION CONNECTION

The 2026 Bari review gave specific attention to pathways connecting aberrant methylation patterns to chronic inflammation and oxidative stress. Pro-inflammatory genes, including those encoding cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), carry methylation-regulated promoter regions. When those promoters lose methylation, gene expression increases. The cell produces more inflammatory signaling molecules. The inflammatory environment the elevated cytokines create then feeds back into the epigenetic machinery, generating further methylation changes that sustain and amplify the inflammatory state.

Tumor suppressor genes, genes that prevent uncontrolled cell division, also carry methylation-regulated promoter regions. When these promoters gain aberrant methylation in cancer-relevant tissue, the tumor suppressor genes silence. The cell loses one of its primary brakes on abnormal proliferation. The 2026 review identified this mechanism across inflammatory, metabolic, and oncological disease categories, establishing aberrant DNA methylation as a shared upstream mechanism across disease categories that clinical medicine typically treats as separate.

THE METABOLIC DISEASE CONNECTION

Metabolic imbalance alters methylation patterns. Obesity, insulin resistance, and chronic hyperglycemia each produce cellular environments that alter DNMT and TET activity. The resulting methylation changes affect the expression of genes governing insulin signaling, lipid metabolism, and adipocyte function, the biological activity of fat storage cells. The 2026 Bari review described metabolic imbalance as a bidirectional participant in aberrant methylation, meaning it both results from and contributes to disrupted methylation patterns.

THE PREDICTIVE POTENTIAL

The 2026 Bari review dedicated substantial attention to the translational potential of DNA methylation-based tests. Aberrant methylation signatures often precede the clinical onset of disease. The review confirmed that current and emerging technologies, including targeted methylation-specific assays and next-generation sequencing approaches, generate methylation profiles with clinically meaningful predictive information. The review concluded that epigenetic profiling carries the potential to identify disease-associated molecular alterations before clinical symptoms emerge, supporting its integration into precision medicine strategies for early risk assessment and personalized prevention.

This means the methylation layer of the genome carries information about disease trajectory that the DNA sequence alone does not. Two people can carry identical DNA sequences at a given gene and produce different disease outcomes because the epigenetic regulation of that gene has diverged in response to different environmental exposures and metabolic histories.

WHY THIS FRAMEWORK MATTERS

The 2026 Bari review represents one of the clearest current scientific articulations of the methylation-genomics framework: that the genome operates as a dynamic system, not a fixed code, and that the methylation layer translating environmental input into gene expression output drives a substantial portion of chronic disease biology. Inflammation, metabolic disease, and cancer do not develop because the DNA sequence changed. They develop because the system that reads the sequence shifted in response to conditions the cell encountered.

Disclaimer: The content on this platform is strictly educational and informational. Nothing here constitutes a medical diagnosis, clinical assessment, or treatment recommendation. All clinical decisions are handled separately through qualified medical providers.